
An investigation was announced on behalf of investors of Allergan, Inc. (NYSE:AGN) shares, who sold any of their NYSE:AGN shares between February 25, 2014 and April 21, 2014, over potential securities laws violations in connection with the proposed acquisition by Valeant Pharmaceuticals.